PAVmed Inc. (NASDAQ:PAVM) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeremy Pearlman - Maxim Group Ed Woo - Ascendiant Capital Operator Good day and welcome to the PAVmed Inc. First Quarter Business Update Call. Today’s conference is being recorded. And now at this time, I’d like to turn the conference over to Adrian Miller. ...

PART I [Business](index=5&type=section&id=Item%201.%20Business) PAVmed Inc. is a commercial-stage medical technology company advancing innovative technologies across four divisions, notably expanding EsoGuard®/EsoCheck® commercialization and forming Veris Health™ in 2021 - PAVmed operates as a multi-product medical technology company with four main divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations[20](index=20&type=chunk) - The company's majority-owned subsidiary, Lucid Diagnostics, Inc. (LUCID), completed an Initial Public Offering (IPO) on October 14, 2021, raising gross proceeds of **$70.0 million**[21](index=21&type=chunk) - In May 2021, PAVmed formed Veris Health, a new majority-owned subsidiary focused on digital health, by acquiring Oncodisc Inc. to improve personalized cancer care through remote patient monitoring[27](index=27&type=chunk)[50](index=50&type=chunk) - Key commercial products include the EsoGuard®/EsoCheck® diagnostic platform for esophageal precancer detection and the CarpX® minimally invasive device for carpal tunnel syndrome, which received FDA 510(k) clearance in April 2020[23](index=23&type=chunk)[27](index=27&type=chunk) [Product Portfolio and Business Lines](index=6&type=section&id=1.1%20Product%20Portfolio%20and%20Business%20Lines) PAVmed's diversified portfolio spans Diagnostics (EsoGuard®, EsoCheck®), Medical Devices (CarpX®, PortIO™), Digital Health (Veris Health™), and Emerging Innovations (DisappEAR™), targeting various medical needs PAVmed Lines-of-Business and Key Products | Line-of-Business | Key Products | | :--- | :--- | | **Diagnostics** | EsoGuard® Esophageal DNA Test, EsoCheck® Esophageal Cell Collection Device, EsoCure™ Esophageal Ablation Device | | **Medical Devices** | CarpX® Minimally Invasive Device, PortIO™ Implantable Vascular Access Device, NextFlo™ IV Infusion Platform | | **Digital Health** | Veris™ cancer healthcare platform and intelligent implantable vascular port | | **Emerging Innovations** | NextVent™ ventilators, DisappEAR™ resorbable ear tubes, Solys™ noninvasive glucose monitoring | - EsoGuard® received a final Medicare payment determination of **$1,938.01**, effective January 1, 2021[28](index=28&type=chunk) - The company is expanding its commercialization efforts for EsoGuard® by targeting primary care physicians and consumers, supported by a network of Lucid Test Centers and a telemedicine partnership with UpScript[31](index=31&type=chunk)[32](index=32&type=chunk) - The Veris Health™ business model aims for **100% recurring revenue** through subscriptions from oncology practices and hospitals for its remote monitoring platform[54](index=54&type=chunk) [Growth and Commercialization Strategy](index=14&type=section&id=1.2%20Growth%20and%20Commercialization%20Strategy) The company's growth strategy focuses on expanding EsoGuard® commercialization across multiple channels, building clinical evidence for regulatory approval and reimbursement, and scaling manufacturing and laboratory capacity - The total addressable U.S. market for EsoGuard is estimated to exceed **$25 billion**, based on the Medicare payment rate and the 13 million at-risk GERD patients recommended for screening[86](index=86&type=chunk) - Key growth strategies include expanding EsoGuard commercialization to PCPs and consumers via Lucid Test Centers and DTC marketing, aggressively expanding clinical evidence for reimbursement and regulatory approvals, scaling manufacturing and establishing an in-house CLIA-certified laboratory, and expanding the product portfolio with synergistic technologies like EsoCure™[87](index=87&type=chunk)[90](index=90&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk) - EsoGuard received FDA **"Breakthrough Device Designation,"** which may expedite its development, assessment, and review for an in-vitro diagnostic (IVD) indication[34](index=34&type=chunk)[96](index=96&type=chunk) - On February 25, 2022, LucidDx Labs Inc., a subsidiary, acquired assets from ResearchDx, Inc. to operate its own CLIA-certified, CAP-accredited clinical laboratory in Lake Forest, CA[92](index=92&type=chunk) [Recent Financing Activities](index=27&type=section&id=1.3%20Recent%20Financing%20Activities) In 2021, PAVmed and its subsidiaries raised approximately **$117.0 million** in gross proceeds, including Lucid Diagnostics' IPO, and secured additional financing commitments in early 2022 - PAVmed and its subsidiaries raised approximately **$117.0 million** in gross proceeds during the year ended December 31, 2021[149](index=149&type=chunk) - In March 2022, PAVmed entered into a Securities Purchase Agreement for up to **$50 million** in Senior Secured Convertible Promissory Notes, with an initial closing for **$27.5 million** in principal[151](index=151&type=chunk) - In March 2022, Lucid Diagnostics established a committed equity facility with Cantor Fitzgerald for up to **$50 million** of its common stock[157](index=157&type=chunk) [Government Regulation](index=30&type=section&id=1.4%20Government%20Regulation) The company's products are subject to extensive FDA regulation, including 510(k), De Novo, or PMA pathways, and ongoing compliance with QSR, healthcare fraud laws, and international certifications like the EU CE mark - Products must be cleared or approved by the FDA before marketing in the U.S., through pathways like 510(k), De Novo, or PMA, with varying levels of required data and scrutiny[170](index=170&type=chunk)[172](index=172&type=chunk) - EsoGuard received FDA **"Breakthrough Device Designation,"** which provides for a more collaborative and expedited review process[96](index=96&type=chunk)[177](index=177&type=chunk) - The company is subject to federal and state healthcare laws, including the Anti-Kickback Statute, False Claims Act, and the Physician Payment Sunshine Act, which regulate business practices and relationships with healthcare providers[183](index=183&type=chunk)[185](index=185&type=chunk)[187](index=187&type=chunk)[189](index=189&type=chunk) - For international marketing, particularly in the European Union, the company must obtain CE mark certification, which is subject to the new, stricter European Medical Device Regulation (EU MDR 2017/745)[194](index=194&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including historical operating losses, the need for substantial future funding, intense competition, reliance on third-party manufacturers, complex regulatory approvals, and potential stock price volatility - The company has a history of operating losses since its 2014 inception and may not achieve profitability[208](index=208&type=chunk) - Significant additional funding may be required to support R&D, clinical trials, and commercialization, and the company may be unable to raise capital when needed[218](index=218&type=chunk) - The business is dependent on third-party manufacturers and a single laboratory facility for its EsoGuard test, posing risks related to capacity, quality control, and operational disruptions[236](index=236&type=chunk)[238](index=238&type=chunk) - The regulatory approval process for medical devices is expensive, time-consuming, and uncertain, and failure to obtain approvals would prevent commercialization[280](index=280&type=chunk) - The COVID-19 pandemic has impacted and may continue to adversely affect operations, supply chains, clinical trials, and demand for products[268](index=268&type=chunk)[272](index=272&type=chunk) [Properties](index=68&type=section&id=Item%202.%20Properties) The company's corporate headquarters is in New York, NY, with additional leased properties for Lucid Test Centers and, post-year-end, expanded facilities for R&D, laboratory, and manufacturing - Corporate headquarters are located at One Grand Central Place, New York, NY on a month-to-month lease[336](index=336&type=chunk) - Subsequent to December 31, 2021, the company has expanded its physical footprint by leasing a **21,019 sq. ft.** CLIA laboratory in California and a **22,288 sq. ft.** light manufacturing facility in Utah, among other properties[337](index=337&type=chunk) [Legal Proceedings](index=68&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in two legal proceedings: a pending settlement for a 2020 stockholder complaint regarding vote counting, and a contested complaint from Benchmark Investments, Inc. concerning financing activities - A stockholder lawsuit from November 2020 concerning vote counting at the 2020 annual meeting has a proposed settlement pending court approval[338](index=338&type=chunk) - Benchmark Investments, Inc. filed a complaint alleging violations of an engagement letter related to financings in late 2020 and early 2021; the company is vigorously contesting the allegations[339](index=339&type=chunk) PART II [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=69&type=section&id=Item%205.%20Market%20for%20Registrant%E2%80%99s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) PAVmed's common stock and Series Z Warrants trade on Nasdaq, with **87.7 million** shares outstanding as of March 2022, and the company does not anticipate paying common stock cash dividends - As of March 29, 2022, there were **87,667,406 shares** of common stock outstanding[344](index=344&type=chunk) - The company has not paid cash dividends on common stock and does not intend to in the foreseeable future[345](index=345&type=chunk) - Dividends on Series B Convertible Preferred Stock accrue at **8% per annum** and were paid-in-kind (PIK) through October 1, 2021; in 2021, dividends of approximately **$288 thousand** were declared and settled via the issuance of **96,292** additional Series B shares[347](index=347&type=chunk)[349](index=349&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=71&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2021, PAVmed recognized its first revenues of **$0.5 million** but incurred a **$50.3 million** net loss due to surging operating expenses, funded by significant financing activities including Lucid's IPO, with management asserting sufficient liquidity for at least one year [Results of Operations](index=74&type=section&id=7.1%20Results%20of%20Operations) In 2021, the company reported **$0.5 million** revenue and a gross loss, with operating expenses surging to **$54.3 million** due to increased sales, marketing, G&A, and R&D, resulting in a **$50.3 million** net loss attributable to PAVmed Inc. Consolidated Results of Operations (in thousands) | | 2021 | 2020 | | :--- | :--- | :--- | | Revenue | $ 500 | $ — | | Cost of revenue | $ 585 | $ — | | **Gross profit (loss)** | **$ (85)** | **$ —** | | Sales and marketing | $ 8,895 | $ 2,789 | | General and administrative | $ 25,566 | $ 9,599 | | Research and development | $ 19,847 | $ 10,963 | | **Total operating expenses** | **$ 54,308** | **$ 23,351** | | **Loss from operations** | **$ (54,393)** | **$ (23,351)** | | **Net loss attributable to PAVmed Inc.** | **$ (50,347)** | **$ (34,276)** | - The **$16.0 million** increase in G&A expenses was primarily due to an **$8.5 million** increase in stock-based compensation, a **$4.2 million** increase in consulting services, and a **$2.2 million** increase in compensation costs[383](index=383&type=chunk) - The **$8.9 million** increase in R&D expenses was mainly driven by a **$7.8 million** increase in development costs for clinical trials and professional fees for key projects like EsoCheck, CarpX, and digital health initiatives[384](index=384&type=chunk) [Liquidity and Capital Resources](index=78&type=section&id=7.2%20Liquidity%20and%20Capital%20Resources) The company's 2021 financing activities provided **$104.3 million** in net cash, primarily from Lucid's IPO and common stock offerings, with management asserting sufficient liquidity for at least one year through existing cash and subsequent financing commitments - The company ended 2021 with **$77.3 million** in cash, a significant increase from **$17.3 million** at the end of 2020[470](index=470&type=chunk) - Net cash used in operating activities was **$40.6 million** in 2021, up from **$21.9 million** in 2020, reflecting increased spending on commercialization and R&D[482](index=482&type=chunk) - Net cash provided by financing activities was **$104.3 million** in 2021, primarily from Lucid's IPO (**$62.0 million** gross) and PAVmed's common stock offerings (**$55.0 million**)[482](index=482&type=chunk) - All convertible notes were repaid in full during the first three months of 2021[398](index=398&type=chunk)[579](index=579&type=chunk) [Critical Accounting Policies](index=81&type=section&id=7.3%20Critical%20Accounting%20Policies) Key critical accounting policies include Revenue Recognition (ASC 606), Stock-Based Compensation (Black-Scholes model), Financial Instruments (fair value option for convertible notes), and Income Taxes (full valuation allowance on deferred tax assets due to operating losses) - **Revenue Recognition:** Follows ASC 606, recognizing revenue as performance obligations are met; for 2021, this related to a commercialization agreement with a fixed monthly fee[408](index=408&type=chunk)[494](index=494&type=chunk) - **Stock-Based Compensation:** Uses the Black-Scholes model for stock options, requiring estimates for inputs like stock price volatility and expected term; the fair value of Lucid's stock prior to its IPO was estimated using a PWERM methodology[506](index=506&type=chunk)[607](index=607&type=chunk) - **Financial Instruments Fair Value:** Convertible notes were measured at fair value (Level 3 inputs) using a Monte Carlo simulation, with changes in value recognized in earnings[411](index=411&type=chunk)[577](index=577&type=chunk) - **Income Taxes:** A full valuation allowance has been established against net deferred tax assets due to the company's history of operating losses, making it more-likely-than-not that these assets will not be realized[420](index=420&type=chunk)[519](index=519&type=chunk) [Controls and Procedures](index=87&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures and internal control over financial reporting were effective as of December 31, 2021, with no material changes reported during the fiscal year - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2021[432](index=432&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of December 31, 2021, based on the COSO 2013 framework[435](index=435&type=chunk) PART III [Directors, Executive Officers, Corporate Governance, Compensation, Security Ownership, and Accountant Fees](index=88&type=section&id=Items%2010%2C%2011%2C%2012%2C%2013%2C%20and%2014) Information for Items 10 through 14, covering directors, executive officers, corporate governance, compensation, security ownership, and accountant fees, is incorporated by reference from the company's definitive 2022 proxy statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's upcoming 2022 proxy statement[440](index=440&type=chunk)[441](index=441&type=chunk)[442](index=442&type=chunk)[443](index=443&type=chunk)[444](index=444&type=chunk) PART IV [Exhibits, Financial Statement Schedules](index=89&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists the financial statements, schedules, and exhibits filed with the Form 10-K, including consolidated financial statements, corporate governance documents, material contracts, and Sarbanes-Oxley certifications - This section contains the list of all exhibits filed with the 10-K, including the company's articles of incorporation, bylaws, material agreements, and executive certifications[449](index=449&type=chunk)[451](index=451&type=chunk) Financial Statements [Report of Independent Registered Public Accounting Firm](index=94&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) Marcum LLP issued an unqualified opinion on the consolidated financial statements, noting the valuation of Lucid Diagnostics Inc. common stock prior to its IPO as a critical audit matter due to complex judgments - The auditor, Marcum LLP, expressed an unqualified opinion on the company's consolidated financial statements[460](index=460&type=chunk) - A Critical Audit Matter was identified concerning the valuation of Lucid Diagnostics Inc. common stock prior to its IPO, due to the subjective and complex judgments required for Level 3 fair value inputs[466](index=466&type=chunk)[467](index=467&type=chunk) [Consolidated Financial Statements](index=96&type=section&id=Consolidated%20Financial%20Statements) The consolidated financial statements show **$87.0 million** in total assets and a **$50.3 million** net loss for 2021, with **$40.6 million** net cash used in operations offset by **$104.3 million** from financing activities Consolidated Balance Sheet Data (in thousands) | | Dec 31, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $ 77,258 | $ 17,256 | | Total current assets | $ 82,637 | $ 18,941 | | **Total assets** | **$ 86,976** | **$ 19,778** | | **Liabilities & Equity** | | | | Total liabilities | $ 7,558 | $ 20,251 | | Total Stockholders' Equity (Deficit) | $ 79,418 | $ (473) | | **Total Liabilities and Stockholders' Equity** | **$ 86,976** | **$ 19,778** | Consolidated Statement of Operations Data (in thousands) | | Year Ended Dec 31, 2021 | Year Ended Dec 31, 2020 | | :--- | :--- | :--- | | Revenue | $ 500 | $ — | | Loss from operations | $ (54,393) | $ (23,351) | | Net loss attributable to PAVmed Inc. | $ (50,347) | $ (34,276) | | Net loss per share (basic and diluted) | $ (0.65) | $ (0.72) | Consolidated Cash Flow Data (in thousands) | | Year Ended Dec 31, 2021 | Year Ended Dec 31, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $ (40,591) | $ (21,914) | | Net cash used in investing activities | $ (3,716) | $ (55) | | Net cash provided by financing activities | $ 104,309 | $ 33,006 | | **Net increase in cash** | **$ 60,002** | **$ 11,037** |

PAVmed Inc. (NASDAQ:PAVM) Q4 2021 Earnings Conference Call March 29, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Anthony Vendetti - Maxim Group. Ed Woo - Ascendiant Capital Markets Operator Greetings. Welcome to the PAVmed Inc. Business Update Conference call. At this time, all participants are in a listen-only mode. A qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______ Commission File Number: 001-37685 PAVmed Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Juri ...

Financial Data and Key Metrics Changes - PAVmed recognized $200,000 of revenues related to EsoGuard with a margin of 28% during Q3 2021, which is not reflective of future margin expectations due to minimum fixed costs during the early ramp [38] - PAVmed reported a net loss attributable to common shareholders of $12.3 million or a loss of $0.15 per common share for Q3 2021, compared to a loss of $5.5 million or $0.11 per share for the same period in 2020 [40] - PAVmed had cash of $37.3 million as of September 30, 2021, and is debt-free [41] Business Line Data and Key Metrics Changes - Lucid recognized $200,000 of revenues related to EsoGuard with a margin of 28% in Q3 2021, with expectations of margins greater than 90% at moderate volumes [42] - Lucid's research and development costs increased to approximately $2.2 million in Q3 2021 from $1.2 million in the prior year, primarily due to increased clinical trial costs [42] - Lucid reported a net loss attributable to common shareholders of $7 million or a loss of $0.49 per common share for Q3 2021, compared to a loss of $2 million or $0.14 per share in the same period in 2020 [44] Market Data and Key Metrics Changes - The EsoGuard test has secured a national Medicare payment rate of $1,938, effective January 2021, with ongoing efforts to secure Medicare coverage and private payer payment [60] - The number of EsoGuard tests performed during Q3 was flat at 203 tests compared to the prior quarter but up over 300% on an annual basis [59] Company Strategy and Development Direction - PAVmed's long-term strategy is to create more Lucids by using its resources to rapidly advance and commercialize innovative technologies [21] - The company plans to expand its infrastructure, including launching dedicated product research and development facilities and a CLIA-certified diagnostic laboratory [24][66] - PAVmed aims to pursue new opportunities through licensing and acquisition of innovative technologies, including later-stage pre-commercial and revenue-generating products [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing COVID-19 pandemic's impact on commercial operations, noting that Lucid's activities are primarily outpatient-based [25] - The management team is hopeful for a draft Local Coverage Decision (LCD) from CMS in the coming months, which could significantly impact reimbursement [90][92] - Management highlighted the importance of primary care physician referrals for the adoption of EsoGuard testing, indicating a strategic shift towards this demographic [96] Other Important Information - PAVmed and Lucid collectively hold approximately $90 million in cash and no debt, marking the strongest financial position since inception [17] - The company has added dozens of employees over the past quarters and expects to accelerate growth in headcount in 2022 [23] Q&A Session Summary Question: Can you walk through the steps regarding the expected timelines for the draft LCD? - Management indicated that they do not expect additional data to be necessary for the draft LCD and are hopeful for a straightforward decision based on existing data [90][91] Question: Where were most EsoCheck procedures performed during Q3, and what are the expectations for early 2022? - Management noted that the majority of tests were performed through traditional GI physicians, with expectations for a shift towards primary care referrals as test centers ramp up [94][96] Question: What feedback has been received from physicians regarding EsoGuard and EsoCheck? - Management reported positive feedback from primary care physicians, highlighting the simplicity of the ask and the effectiveness of the messaging [100][103]

Nasdaq: PAVM, PAVMZ Innovating at the Speed of Life™ Lishan Aklog M.D. Chairman & CEO Dennis McGrath President & CFO September 14-15, 2021 Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. • Actual results and events may differ significantly from results and events discussed in forward-looking statements. • Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual R ...

PART I FINANCIAL INFORMATION [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Despite no revenue and increased net loss from higher operating expenses, the company significantly strengthened its balance sheet with cash increasing to **$43.2 million** and equity turning positive to **$42.0 million** through financing and debt repayment [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $43,210 | $17,256 | | Total current assets | $46,336 | $18,941 | | **Total assets** | **$47,371** | **$19,778** | | **Liabilities & Equity** | | | | Total liabilities | $5,331 | $20,251 | | Total Stockholders' Equity (Deficit) | $42,040 | $(473) | | **Total Liabilities and Stockholders' Equity** | **$47,371** | **$19,778** | - The company's financial position improved significantly, with **cash increasing by 150%** and **total liabilities decreasing by 74%** from Dec 31, 2020 to June 30, 2021, primarily driven by the repayment of all senior convertible notes[10](index=10&type=chunk) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) - The company generated **no revenue** in the three and six months ended June 30, 2021 and 2020[13](index=13&type=chunk) Operating Results Highlights (in thousands, except per share data) | Metric | Q2 2021 | Q2 2020 | 6 Months 2021 | 6 Months 2020 | | :--- | :--- | :--- | :--- | :--- | | Total operating expenses | $12,970 | $5,014 | $21,046 | $10,268 | | Loss from operations | $(12,970) | $(5,014) | $(21,046) | $(10,268) | | Net loss attributable to PAVmed Inc. | $(11,471) | $(5,578) | $(20,902) | $(20,053) | | Net loss per share (basic and diluted) | $(0.14) | $(0.12) | $(0.27) | $(0.45) | - Operating expenses **more than doubled in Q2 2021** compared to Q2 2020, driven by increases in commercial operations, general and administrative, and research and development activities[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Highlights for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(15,796) | $(9,346) | | Net cash used in investing activities | $(204) | $(44) | | Net cash provided by financing activities | $41,954 | $10,251 | | **Net increase in cash** | **$25,954** | **$861** | | **Cash, end of period** | **$43,210** | **$7,080** | - Financing activities in the first six months of 2021 provided **$42.0 million in net cash**, primarily from registered common stock offerings (**$55.0 million**) and warrant exercises (**$2.8 million**), which was partially offset by the repayment of convertible notes (**$14.8 million**)[23](index=23&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) - On May 28, 2021, the company's subsidiary Veris Health Inc. acquired Oncodisc Inc. for total consideration of approximately **$261k**, accounted for as an asset acquisition with **$133k** allocated to in-process R&D and expensed immediately[44](index=44&type=chunk) - All outstanding convertible notes were fully repaid during Q1 2021, with the November 2019 note settled with stock and the April 2020 and August 2020 notes repaid with cash totaling **$14.8 million**[57](index=57&type=chunk)[58](index=58&type=chunk)[62](index=62&type=chunk) - A **$300k PPP loan** received in April 2020 was fully forgiven in June 2021, resulting in a **gain of $300k**[66](index=66&type=chunk) - Consolidated stock-based compensation expense increased significantly to **$6.6 million** for the six months ended June 30, 2021, up from **$0.9 million** in the same period of 2020, largely due to new restricted stock awards granted under the Lucid Diagnostics Inc. 2018 Equity Plan[80](index=80&type=chunk)[75](index=75&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=31&type=section&id=Item%202%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's transition to a commercial-stage entity with a multi-product pipeline, noting sharply increased operating expenses, and significantly improved liquidity to **$43.2 million** in cash, sufficient for at least one year [Overview of Business and Products](index=32&type=section&id=Overview%20of%20Business%20and%20Products) - PAVmed operates as a multi-product, commercial-stage medical device company with five lines of business: GI Health, Minimally Invasive Interventions, Infusion Therapy, Digital Health, and Emerging Innovations[109](index=109&type=chunk)[117](index=117&type=chunk) - Key commercial products include EsoGuard/EsoCheck for esophageal cancer screening and CarpX for carpal tunnel syndrome, both receiving European CE Mark certification in May 2021, expanding market access[112](index=112&type=chunk)[129](index=129&type=chunk) - The company is expanding its commercialization strategy for EsoGuard by targeting primary care physicians (PCPs) and establishing Lucid Test Centers, with the first three opened in Phoenix, AZ[120](index=120&type=chunk) - In May 2021, the company formed a new majority-owned subsidiary, Veris Health Inc., which acquired Oncodisc Inc. to enter the digital health market with an intelligent implantable vascular access port for remote patient monitoring in cancer care[112](index=112&type=chunk)[136](index=136&type=chunk) [Results of Operations Comparison](index=39&type=section&id=Results%20of%20Operations%20Comparison) Comparison of Operating Expenses (in millions) | Expense Category | Q2 2021 | Q2 2020 | 6 Months 2021 | 6 Months 2020 | | :--- | :--- | :--- | :--- | :--- | | Commercial operations | $2.0 | $0.5 | $3.4 | $0.8 | | General and administrative | $6.7 | $2.4 | $10.1 | $4.7 | | Research and development | $4.3 | $2.1 | $7.6 | $4.7 | - The increase in Commercial operations expenses was driven by higher staffing for sales and marketing and increased consulting fees[157](index=157&type=chunk)[163](index=163&type=chunk) - General and administrative expenses rose primarily due to increased staffing levels and higher stock-based compensation[158](index=158&type=chunk)[164](index=164&type=chunk) - Research and development costs increased due to higher development and consulting fees for key projects including CarpX, NextFlo, PortIO, EsoCure, and digital health initiatives[158](index=158&type=chunk)[164](index=164&type=chunk) - In H1 2021, the company recognized a **$3.7 million loss** from debt extinguishment related to the full repayment of its convertible notes and a **$0.3 million gain** from the forgiveness of its PPP loan[168](index=168&type=chunk)[165](index=165&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) - The company had **$43.2 million in cash** as of June 30, 2021, and expects this to be sufficient to fund operations for at least one year[172](index=172&type=chunk) - In the first six months of 2021, the company raised approximately **$57.8 million in gross proceeds** from two registered direct offerings of common stock and the exercise of Series Z Warrants[173](index=173&type=chunk)[174](index=174&type=chunk)[175](index=175&type=chunk) - During H1 2021, the company used a portion of its cash to repay in-full all outstanding principal balances of its convertible notes[173](index=173&type=chunk)[176](index=176&type=chunk) [Controls and Procedures](index=44&type=section&id=Item%204%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of June 30, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures were effective as of June 30, 2021[179](index=179&type=chunk) - No changes occurred during the fiscal period ended June 30, 2021, that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[180](index=180&type=chunk) PART II OTHER INFORMATION [Legal Proceedings](index=45&type=section&id=Item%201%20Legal%20Proceedings) The company is involved in two legal proceedings: a stockholder complaint pending non-monetary settlement and a **$1.3 million** damages claim from Benchmark Investments, Inc. which it plans to contest - A stockholder complaint filed in November 2020 regarding the counting of broker non-votes at the July 2020 Annual Meeting is pending settlement, subject to court approval and not contemplating monetary damages[46](index=46&type=chunk)[182](index=182&type=chunk) - Benchmark Investments, Inc. filed a complaint in December 2020 seeking up to **$1.3 million** in damages related to registered direct offerings, which the company disagrees with and plans to contest vigorously[47](index=47&type=chunk)[182](index=182&type=chunk) [Other Information](index=45&type=section&id=Item%205%20Other%20Information) This section reports no other information - None[184](index=184&type=chunk) [Exhibits](index=45&type=section&id=Item%206%20Exhibits) This section lists the exhibits filed as part of the Quarterly Report on Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer - The exhibits filed with this Form 10-Q are listed in the Exhibit Index[184](index=184&type=chunk)

PAVmed Inc. (NASDAQ:PAVM) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Mike Havrilla - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Frank Takkinen - Lake Street Capital Ed Woo - Ascendiant Capital Markets Jeremy Pearlman - Maxim Group Operator Greetings, and welcome to the PAVmed Inc. Business Update Conference call. At this time, all participants are in a listen-only mode. A question-and-answer session wil ...

PAVmed Inc. (NASDAQ:PAVM) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Mike Havrilla - Director of Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - President & Chief Financial Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Frank Ibarra - IbarMax, LLC Operator Greetings, and welcome to the PAVmed Inc. Business Updat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______ Commission File Number: 001-37685 PAVmed Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Juri ...